Myriad Genetics, Inc. (MYGN)
Nasdaq: MYGN · In Vitro & In Vivo Diagnostic Substances · Salt Lake City, UT · filing with the SEC since 1996
Who owns Myriad Genetics, Inc.
As filed with the SECHolders of 5% or more
5
BlackRock Portfolio Management LLC holds 8.6% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
21
report now, of 45 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
BlackRock Portfolio Management LLC
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 10.4% in Sep 4, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 7, 2026 · Common Stock · 15.3% in Jul 17, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Feb 11, 2026 · Common Stock, par value $0.01 per share · 5.1% in Nov 12, 2025
Vestal Point Capital, LP
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.01 per share
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · 4.7% in May 12, 2026
Barclays PLC
SCHEDULE 13G/A · filed Nov 12, 2025 · COMMON-STOCK · reported falling below 5%, from 5.31% in Aug 12, 2025
Camber Capital Management LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.01 per share · reported falling below 5%
Disciplined Growth Investors Inc /mn
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock · reported falling below 5%, from 5.1% in May 15, 2025
Glenview Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.01 per share · reported falling below 5%, from 5.3% in Jan 13, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 8.47% in Oct 31, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 12, 2025 · Common Stock · reported falling below 5%, from 5% in May 12, 2025
What MYGN reports owning in othersstakes of 5% or more, and other ties
8 subsidiaries in 5 countries, from the list filed with the 10-K filed Feb 24, 2026.
Insider tradesForm 4
1sales
5purchases
1sales on a scheduled plan
1people selling
$100,000sold, in dollars
$700,000bought, in dollars
Open-market trades on Form 4 from Nov 9, 2025 to Nov 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 45 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kumar Rashmi | director | 1 | $100,000 | 1 | 0 | $0 |
| Phanstiel S. Louise | director | 0 | $0 | 0 | 3 | $500,000 |
| Raha Samraat S. | President and CEO | 0 | $0 | 0 | 1 | $200,000 |
| Bisaro Paul | director | 0 | $0 | 0 | 1 | $0 |